LAS VEGAS, July 12, 2018 /PRNewswire/ -- Digipath, Inc. (DIGP), a service-oriented independent testing laboratory and media firm focused on the developing cannabis market, is pleased to announce that Dr. Yunfeng Pan, PhD, has joined Digipath Labs as its Analytical Laboratory Director with oversight of analytical testing procedures.
Dr. Pan brings to Digipath key skills in organizational leadership, project management, and complex problem solving from working in highly-regulated environments including those at Oak Ridge National Laboratory in Tennessee and Rio Valley Biofuels in El Paso, Texas where she served as laboratory compliance manager.
Dr. Pan is also certified in OSHA Industry Safety and Health Training and will serve as Digipath Labs' chemical hygiene and safety officer.
Digipath's Chief Science Officer Cindy Orser, PhD, commented, "The addition of Dr. Pan greatly enhances the Digipath Labs team. She will be a decisive co-leader in the laboratory by providing critical oversight of day-to-day chemical hygiene and analytical operations."
Todd Denkin, Chief Executive Officer of Digipath, added, "We welcome Dr. Pan to the Digipath team and have already seen a positive impact on the lab's operations. Our goal is to always improve and innovate, and we look forward to Dr. Pan's contributions as we move along with our ISO certification and servicing our Nevada clients."
About Digipath, Inc.
Digipath, Inc. supports the cannabis industry's best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
Investor Relations Contact
Viridian Capital Advisors, LLC
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
View original content with multimedia:http://www.prnewswire.com/news-releases/dr-yunfeng-pan-joins-digipath-labs-as-analytical-laboratory-director-300679906.html